Zymeworks (ZYME) Financials

$11.31 +0.31 (+2.85%)

As of 10:25 AM Eastern

Annual Income Statements for Zymeworks

This table shows Zymeworks' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-181	-212	124	-119	-123
Consolidated Net Income / (Loss)	-181	-212	124	-119	-123
Net Income / (Loss) Continuing Operations	-181	-212	124	-119	-123
Total Pre-Tax Income	-180	-212	135	-119	-117
Total Operating Income	-187	-216	131	-138	-137
Total Gross Profit	39	27	412	76	76
Total Revenue	39	27	412	76	76
Operating Revenue	39	27	412	76	76
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	226	242	282	214	213
Selling, General & Admin Expense	55	43	73	70	62
Research & Development Expense	171	200	209	144	135
Impairment Charge	-	-	0.00	0.00	17
Total Other Income / (Expense), net	7.35	3.27	4.71	19	20
Interest & Investment Income	5.70	1.97	3.60	20	20
Other Income / (Expense), net	1.65	1.31	1.11	-0.89	0.56
Income Tax Expense	0.43	-0.52	11	-0.57	6.08
Basic Earnings per Share	($3.58)	($4.11)	$1.91	($1.72)	($1.62)
Weighted Average Basic Shares Outstanding	50.38M	51.55M	65.19M	68.86M	75.85M
Diluted Earnings per Share	($3.58)	($4.61)	$1.90	($1.72)	($1.62)
Weighted Average Diluted Shares Outstanding	50.38M	52.13M	65.25M	68.86M	75.88M
Weighted Average Basic & Diluted Shares Outstanding	-	-	64.04M	70.57M	69.58M

This table shows Zymeworks' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-48	309	-24	-53	-29	-13	-33	-38	-28	-24
Consolidated Net Income / (Loss)	-48	309	-24	-51	-29	-14	-32	-38	-30	-24
Net Income / (Loss) Continuing Operations	-48	309	-24	-51	-29	-14	-32	-38	-30	-24
Total Pre-Tax Income	-48	320	-23	-49	-28	-19	-32	-38	-30	-18
Total Operating Income	-50	319	-27	-54	-33	-23	-38	-43	-34	-22
Total Gross Profit	2.63	402	36	7.00	17	17	10	19	16	31
Total Revenue	2.63	402	36	7.00	17	17	10	19	16	31
Operating Revenue	2.63	402	36	7.00	17	17	10	19	16	31
Total Operating Expenses	53	83	63	61	50	40	48	62	50	53
Selling, General & Admin Expense	16	30	17	22	17	15	16	16	14	16
Research & Development Expense	37	53	46	39	33	26	32	46	36	20
Total Other Income / (Expense), net	2.48	1.04	4.32	4.62	5.66	4.22	6.22	5.27	4.58	4.43
Interest & Investment Income	1.13	1.73	4.81	4.83	5.03	5.05	5.92	5.15	4.79	4.08
Other Income / (Expense), net	1.36	-0.69	-0.49	-0.21	0.63	-0.83	0.30	0.11	-0.20	0.34
Income Tax Expense	-0.03	11	1.39	1.65	1.11	-4.72	0.08	0.07	0.23	5.72
Basic Earnings per Share	($0.72)	$4.78	($0.36)	($0.76)	($0.41)	($0.19)	($0.42)	($0.49)	($0.39)	($0.32)
Weighted Average Basic Shares Outstanding	66.48M	65.19M	66.74M	67.28M	70.58M	68.86M	76.21M	76.39M	76.13M	75.85M
Diluted Earnings per Share	($0.72)	$4.78	($0.37)	($0.76)	($0.41)	($0.18)	($0.42)	($0.49)	($0.39)	($0.32)
Weighted Average Diluted Shares Outstanding	66.48M	65.25M	66.74M	67.28M	70.58M	68.86M	76.25M	76.40M	76.16M	75.88M
Weighted Average Basic & Diluted Shares Outstanding	-	64.04M	64.17M	67.83M	70.00M	70.57M	70.70M	71.05M	68.88M	69.58M

This table details how cash moves in and out of Zymeworks' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	114	-40	199	-243	-91
Net Cash From Operating Activities	-151	-192	144	-118	-110
Net Cash From Continuing Operating Activities	-151	-192	144	-118	-110
Net Income / (Loss) Continuing Operations	-181	-212	124	-119	-123
Consolidated Net Income / (Loss)	-181	-212	124	-119	-123
Depreciation Expense	3.36	3.74	6.22	7.46	4.19
Amortization Expense	6.92	5.84	5.78	9.84	7.01
Non-Cash Adjustments To Reconcile Net Income	29	10	2.06	8.74	34
Changes in Operating Assets and Liabilities, net	-9.58	-0.35	5.71	-26	-32
Net Cash From Investing Activities	-43	145	-54	-207	39
Net Cash From Continuing Investing Activities	-43	145	-54	-207	39
Purchase of Property, Plant & Equipment	-4.31	-12	-8.15	-2.47	-1.99
Acquisitions	-1.96	-0.88	-4.98	-1.60	-1.08
Purchase of Investments	-37	-35	-113	-553	-284
Sale and/or Maturity of Investments	-	193	72	350	326
Net Cash From Financing Activities	309	8.01	109	82	-20
Net Cash From Continuing Financing Activities	308	8.01	109	82	-20
Repurchase of Common Equity	-	-	0.00	0.00	-30
Issuance of Common Equity	308	8.50	109	82	9.79
Other Financing Activities, net	-0.04	-0.49	-0.61	-0.07	-0.19
Effect of Exchange Rate Changes	-0.55	-0.33	0.20	0.35	0.29
Cash Income Taxes Paid	-	-	10	0.17	3.18

This table details how cash moves in and out of Zymeworks' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-103	305	-219	-39	-48	63	-43	-44	51	-56
Net Cash From Operating Activities	-73	327	-83	-6.40	-43	14	-38	-25	-5.88	-42
Net Cash From Continuing Operating Activities	-73	327	-83	-6.40	-43	14	-38	-25	-5.88	-42
Net Income / (Loss) Continuing Operations	-48	309	-24	-51	-29	-14	-32	-38	-30	-24
Consolidated Net Income / (Loss)	-48	309	-24	-51	-29	-14	-32	-38	-30	-24
Depreciation Expense	1.39	1.15	1.58	1.94	2.40	1.54	1.06	1.10	1.04	1.00
Amortization Expense	0.81	1.16	1.32	2.58	4.14	1.81	1.25	1.43	1.63	2.69
Non-Cash Adjustments To Reconcile Net Income	2.98	4.80	2.03	0.80	1.52	4.39	3.07	22	4.80	4.13
Changes in Operating Assets and Liabilities, net	-30	11	-64	39	-22	21	-11	-11	17	-26
Net Cash From Investing Activities	-30	-22	-138	-61	-7.02	-1.34	-7.32	-20	72	-6.21
Net Cash From Continuing Investing Activities	-30	-22	-138	-61	-7.02	-1.34	-7.32	-20	72	-6.21
Purchase of Property, Plant & Equipment	-0.98	-0.35	-0.39	-0.80	-0.93	-0.36	-0.19	-0.59	-0.90	-0.31
Purchase of Investments	-70	25	-182	-184	-125	-62	-67	-111	-53	-54
Sale and/or Maturity of Investments	43	-46	44	124	119	62	60	92	126	48
Net Cash From Financing Activities	0.63	-0.38	1.74	28	1.90	51	2.12	1.05	-15	-8.64
Net Cash From Continuing Financing Activities	0.63	-0.38	1.74	28	1.90	51	2.12	1.05	-15	-8.64
Repurchase of Common Equity	-	-	-	-	-	-	-	-	-	-9.43
Issuance of Common Equity	0.64	0.14	1.75	28	1.91	51	2.13	1.13	5.74	0.79
Other Financing Activities, net	-0.01	-0.52	-0.01	-0.02	-0.02	-0.02	-0.01	-0.09	-0.10	-0.00
Effect of Exchange Rate Changes	0.25	-0.09	0.35	-0.01	0.02	-0.00	0.12	0.06	-0.01	0.11

This table presents Zymeworks' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024
Total Assets	389	649	581	463
Total Current Assets	288	545	413	300
Cash & Equivalents	202	401	158	66
Short-Term Investments	51	91	217	160
Accounts Receivable	16	33	19	56
Prepaid Expenses	20	19	19	19
Plant, Property, & Equipment, net	23	25	20	18
Total Noncurrent Assets	78	79	148	145
Long-Term Investments	0.89	0.89	82	98
Goodwill	12	12	12	12
Intangible Assets	21	26	25	4.58
Noncurrent Deferred & Refundable Income Taxes	3.07	1.35	3.62	4.39
Other Noncurrent Operating Assets	41	39	25	26
Total Liabilities & Shareholders' Equity	389	649	581	463
Total Liabilities	140	156	116	124
Total Current Liabilities	72	96	56	88
Accounts Payable	63	87	46	60
Current Deferred Revenue	0.00	2.35	3.70	26
Current Deferred & Payable Income Tax Liabilities	0.00	0.84	1.81	0.13
Other Current Liabilities	9.06	4.96	4.26	2.74
Total Noncurrent Liabilities	68	60	60	36
Noncurrent Deferred Revenue	33	31	33	15
Noncurrent Deferred & Payable Income Tax Liabilities	1.57	1.79	3.30	4.76
Other Noncurrent Operating Liabilities	34	28	24	17
Commitments & Contingencies	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	249	493	465	339
Total Preferred & Common Equity	249	493	465	339
Preferred Stock	0.00	0.00	0.00	0.00
Total Common Equity	249	493	465	339
Common Stock	939	1,038	1,140	1,168
Retained Earnings	-683	-559	-677	-830
Accumulated Other Comprehensive Income / (Loss)	-6.66	-6.66	-6.60	-6.95
Other Equity Adjustments	0.00	20	9.35	8.19

This table presents Zymeworks' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	601	602	556	554	516	487
Total Current Assets	426	420	375	394	383	344
Cash & Equivalents	182	142	94	115	71	122
Short-Term Investments	159	198	201	230	259	175
Accounts Receivable	67	49	67	31	32	24
Prepaid Expenses	19	31	12	18	21	23
Plant, Property, & Equipment, net	24	22	21	19	18	18
Total Noncurrent Assets	151	159	161	141	114	125
Long-Term Investments	72	92	96	75	66	78
Goodwill	12	12	12	12	12	12
Intangible Assets	26	25	26	25	7.45	6.58
Noncurrent Deferred & Refundable Income Taxes	1.41	1.36	1.32	3.70	3.95	4.21
Other Noncurrent Operating Assets	39	29	26	25	24	25
Total Liabilities & Shareholders' Equity	601	602	556	554	516	487
Total Liabilities	127	153	132	116	109	120
Total Current Liabilities	67	94	73	57	55	84
Accounts Payable	59	70	68	47	44	52
Current Deferred Revenue	2.35	18	0.09	3.44	5.52	27
Current Deferred & Payable Income Tax Liabilities	0.84	1.16	0.83	1.86	1.93	2.07
Other Current Liabilities	4.88	4.71	4.13	4.16	2.84	2.94
Total Noncurrent Liabilities	60	60	59	59	55	36
Noncurrent Deferred Revenue	31	31	33	33	33	15
Noncurrent Deferred & Payable Income Tax Liabilities	1.86	1.92	1.97	3.35	3.40	3.46
Other Noncurrent Operating Liabilities	27	27	24	23	18	18
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	474	449	424	438	406	367
Total Preferred & Common Equity	474	449	424	438	406	367
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	474	449	424	438	406	367
Common Stock	1,053	1,082	1,086	1,147	1,153	1,163
Retained Earnings	-583	-634	-663	-709	-747	-798
Accumulated Other Comprehensive Income / (Loss)	-5.94	-7.81	-8.30	-7.72	-7.90	-6.00
Other Equity Adjustments	9.43	9.35	9.35	8.19	8.19	8.19

This table displays calculated financial ratios and metrics derived from Zymeworks' official financial filings.

Metric	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	-31.50%	1,446.03%	-81.57%	0.38%
EBITDA Growth	0.00%	-16.63%	170.16%	-184.68%	-3.06%
EBIT Growth	0.00%	-15.34%	161.42%	-205.55%	1.72%
NOPAT Growth	0.00%	-15.02%	179.51%	-180.52%	0.68%
Net Income Growth	0.00%	-17.33%	158.69%	-195.44%	-3.39%
EPS Growth	0.00%	-28.77%	141.21%	-190.53%	5.81%
Operating Cash Flow Growth	0.00%	-27.11%	174.88%	-182.09%	6.98%
Free Cash Flow Firm Growth	0.00%	0.00%	179.00%	-190.99%	3.19%
Invested Capital Growth	0.00%	0.00%	96.32%	5,377.16%	70.36%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	-83.53%	22.68%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-155.22%	2.12%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-168.11%	1.71%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-150.68%	0.87%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	-157.82%	-7.94%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-153.09%	-9.46%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	-160.64%	-101.61%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-83.22%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	-74.30%	284.61%
Profitability Metrics	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-450.67%	-767.40%	34.82%	-160.03%	-164.29%
Operating Margin	-481.29%	-808.22%	31.64%	-181.62%	-179.69%
EBIT Margin	-477.06%	-803.31%	31.91%	-182.80%	-178.96%
Profit (Net Income) Margin	-463.54%	-794.01%	30.14%	-156.13%	-160.80%
Tax Burden Percent	100.24%	99.76%	91.95%	99.52%	105.22%
Interest Burden Percent	96.93%	99.08%	102.73%	85.82%	85.40%
Effective Tax Rate	0.00%	0.00%	8.05%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-2,304.45%	-830.50%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-2,299.81%	-823.66%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	2,279.67%	799.97%
Return on Equity (ROE)	0.00%	-85.05%	33.51%	-24.78%	-30.54%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	-1,232.29%	-882.55%
Operating Return on Assets (OROA)	0.00%	-55.08%	25.37%	-22.60%	-26.16%
Return on Assets (ROA)	0.00%	-54.44%	23.96%	-19.30%	-23.51%
Return on Common Equity (ROCE)	0.00%	-85.05%	33.51%	-24.78%	-30.54%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-85.05%	25.22%	-25.53%	-36.22%
Net Operating Profit after Tax (NOPAT)	-131	-151	120	-97	-96
NOPAT Margin	-336.90%	-565.75%	29.10%	-127.13%	-125.78%
Net Nonoperating Expense Percent (NNEP)	0.00%	-48.05%	1.16%	-4.64%	-6.85%
Return On Investment Capital (ROIC_SIMPLE)	-	-	24.35%	-20.79%	-28.33%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	141.76%	159.52%	17.78%	92.68%	80.61%
R&D to Revenue	439.53%	748.70%	50.57%	188.94%	176.43%
Operating Expenses to Revenue	581.29%	908.22%	68.36%	281.62%	279.69%
Earnings before Interest and Taxes (EBIT)	-186	-214	132	-139	-137
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-176	-205	144	-122	-125
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	1.00	1.41	2.72
Price to Tangible Book Value (P/TBV)	0.00	0.00	1.09	1.53	2.86
Price to Revenue (P/Rev)	0.00	0.00	1.20	8.61	12.09
Price to Earnings (P/E)	0.00	0.00	3.98	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	25.11%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	23.19	41.06
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	2.61	7.84
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.01	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.02	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.02	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.01	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.02	0.00	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-1.02	-1.01	-0.99	-0.97
Leverage Ratio	0.00	1.56	1.40	1.28	1.30
Compound Leverage Factor	0.00	1.55	1.44	1.10	1.11
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	0.00	2.84	1.83	1.68
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-
Current Ratio	0.00	4.01	5.70	7.41	3.40
Quick Ratio	0.00	3.73	5.50	7.06	3.19
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-147	116	-105	-102
Operating Cash Flow to CapEx	-3,512.83%	-1,551.52%	1,768.21%	-4,781.85%	-5,527.07%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.00	0.07	0.79	0.12	0.15
Accounts Receivable Turnover	0.00	1.71	16.83	2.88	2.03
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	1.17	17.37	3.41	4.07
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	213.61	21.69	126.95	180.08
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	213.61	21.69	126.95	180.08
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	0.00	-4.40	-0.16	8.55	15
Invested Capital Turnover	0.00	-12.13	-180.83	18.13	6.60
Increase / (Decrease) in Invested Capital	0.00	-4.40	4.24	8.71	6.02
Enterprise Value (EV)	0.00	0.00	2.03	198	598
Market Capitalization	0.00	0.00	495	655	922
Book Value per Share	$0.00	$4.83	$7.56	$6.64	$4.92
Tangible Book Value per Share	$0.00	$4.18	$6.97	$6.11	$4.68
Total Capital	0.00	249	493	465	339
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-253	-493	-456	-324
Capital Expenditures (CapEx)	4.31	12	8.15	2.47	1.99
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-36	-43	-17	-14
Debt-free Net Working Capital (DFNWC)	0.00	216	449	357	212
Net Working Capital (NWC)	0.00	216	449	357	212
Net Nonoperating Expense (NNE)	49	61	-4.33	22	27
Net Nonoperating Obligations (NNO)	0.00	-253	-493	-456	-324
Total Depreciation and Amortization (D&A)	10	9.58	12	17	11
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-135.84%	-10.46%	-22.58%	-17.85%
Debt-free Net Working Capital to Revenue	0.00%	810.97%	108.87%	469.88%	278.04%
Net Working Capital to Revenue	0.00%	810.97%	108.87%	469.88%	278.04%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$1.91	($1.72)	($1.62)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	65.19M	68.86M	75.85M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$1.90	($1.72)	($1.62)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	65.25M	68.86M	75.88M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	64.04M	70.57M	69.58M
Normalized Net Operating Profit after Tax (NOPAT)	-131	-151	120	-97	-84
Normalized NOPAT Margin	-336.90%	-565.75%	29.10%	-127.13%	-109.92%
Pre Tax Income Margin	-462.43%	-795.95%	32.79%	-156.87%	-152.82%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	-24.49%

This table displays calculated financial ratios and metrics derived from Zymeworks' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	1,756.89%	28.67%	527.37%	-95.79%	-71.81%	174.82%	-3.07%	83.33%
EBITDA Growth	0.00%	0.00%	63.25%	20.81%	44.32%	-106.51%	-41.49%	19.20%	-21.80%	13.02%
EBIT Growth	0.00%	0.00%	61.96%	16.51%	33.46%	-107.61%	-35.04%	21.26%	-5.54%	9.81%
NOPAT Growth	0.00%	0.00%	62.47%	17.79%	34.00%	-105.32%	-38.57%	20.75%	-2.91%	5.14%
Net Income Growth	0.00%	0.00%	66.47%	20.84%	40.04%	-104.68%	-29.98%	26.33%	-4.05%	-62.31%
EPS Growth	0.00%	0.00%	68.91%	21.65%	43.06%	-103.77%	-13.51%	35.53%	4.88%	-77.78%
Operating Cash Flow Growth	0.00%	0.00%	-50.13%	88.33%	41.56%	-95.74%	54.72%	-290.53%	86.23%	-397.46%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	120.54%	56.59%	130.44%	14.10%
Invested Capital Growth	0.00%	0.00%	0.00%	0.00%	0.00%	5,377.16%	-70.96%	-38.41%	-123.72%	70.36%
Revenue Q/Q Growth	-51.65%	15,198.10%	-91.16%	-80.32%	135.73%	2.54%	-40.74%	91.85%	-16.85%	93.94%
EBITDA Q/Q Growth	25.58%	785.82%	-107.75%	-100.28%	47.67%	19.79%	-68.31%	-14.37%	21.11%	42.72%
EBIT Q/Q Growth	24.69%	750.41%	-108.71%	-95.63%	39.98%	25.61%	-54.61%	-14.06%	19.55%	36.43%
NOPAT Q/Q Growth	23.49%	974.95%	-106.19%	-98.36%	38.58%	29.53%	-61.40%	-13.45%	20.24%	35.05%
Net Income Q/Q Growth	25.96%	746.72%	-107.87%	-110.04%	43.92%	49.52%	-118.57%	-19.06%	20.79%	21.25%
EPS Q/Q Growth	25.77%	763.89%	-107.74%	-105.41%	46.05%	56.10%	-133.33%	-16.67%	20.41%	17.95%
Operating Cash Flow Q/Q Growth	-33.18%	548.35%	-125.41%	92.31%	-566.78%	132.70%	-369.95%	33.66%	76.48%	-606.28%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	31.37%	-3.77%	55.59%	165.52%	-245.02%	172.78%	-225.32%
Invested Capital Q/Q Growth	0.00%	0.00%	37,305.56%	-72.47%	100.45%	-74.30%	110.13%	-41.61%	-177.18%	284.61%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-1,779.06%	79.76%	-69.90%	-711.31%	-157.90%	-123.51%	-350.81%	-209.13%	-198.41%	-58.60%
Operating Margin	-1,914.03%	79.35%	-76.68%	-772.84%	-201.36%	-138.37%	-376.89%	-222.87%	-213.78%	-71.60%
EBIT Margin	-1,862.41%	79.18%	-78.05%	-775.82%	-197.52%	-143.29%	-373.86%	-222.27%	-215.06%	-70.49%
Profit (Net Income) Margin	-1,818.55%	76.88%	-68.45%	-730.53%	-173.80%	-85.56%	-315.58%	-195.84%	-186.56%	-75.75%
Tax Burden Percent	99.94%	96.57%	106.05%	103.34%	104.03%	75.41%	100.24%	100.18%	100.76%	132.12%
Interest Burden Percent	97.70%	100.54%	82.70%	91.12%	84.58%	79.18%	84.21%	87.95%	86.09%	81.34%
Effective Tax Rate	0.00%	3.43%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-794.62%	-29,189.68%	-3,911.83%	-1,755.72%	-342.34%	-729.59%	-733.63%	-330.91%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-792.08%	-29,183.54%	-3,909.05%	-1,756.12%	-341.10%	-727.74%	-732.08%	-328.87%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	691.26%	28,104.72%	3,602.63%	1,740.74%	311.99%	704.92%	708.61%	319.41%
Return on Equity (ROE)	0.00%	33.51%	-103.36%	-1,084.96%	-309.20%	-14.98%	-30.35%	-24.67%	-25.02%	-11.50%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	-1,232.29%	-157.46%	-669.51%	0.00%	-882.55%
Operating Return on Assets (OROA)	0.00%	62.94%	-57.96%	-576.92%	-163.87%	-17.72%	-32.68%	-24.94%	-25.64%	-10.30%
Return on Assets (ROA)	0.00%	61.11%	-50.83%	-543.25%	-144.19%	-10.58%	-27.59%	-21.97%	-22.24%	-11.07%
Return on Common Equity (ROCE)	0.00%	33.51%	-103.36%	-1,084.96%	-309.20%	-14.98%	-30.35%	-24.67%	-25.02%	-11.50%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	36.45%	41.45%	48.37%	0.00%	-28.76%	-27.70%	-30.97%	0.00%
Net Operating Profit after Tax (NOPAT)	-35	308	-19	-38	-23	-16	-26	-30	-24	-16
NOPAT Margin	-1,339.82%	76.63%	-53.68%	-540.99%	-140.95%	-96.86%	-263.82%	-156.01%	-149.65%	-50.12%
Net Nonoperating Expense Percent (NNEP)	0.00%	0.20%	-2.54%	-6.14%	-2.77%	0.40%	-1.25%	-1.85%	-1.54%	-2.04%
Return On Investment Capital (ROIC_SIMPLE)	-	62.57%	-	-	-	-3.53%	-	-	-	-4.59%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	604.03%	7.49%	47.63%	310.03%	102.80%	87.58%	157.43%	81.48%	86.58%	52.16%
R&D to Revenue	1,410.00%	13.16%	129.05%	562.81%	198.56%	150.80%	319.46%	241.39%	227.21%	63.73%
Operating Expenses to Revenue	2,014.03%	20.65%	176.68%	872.84%	301.36%	238.37%	476.89%	322.87%	313.78%	171.60%
Earnings before Interest and Taxes (EBIT)	-49	319	-28	-54	-33	-24	-37	-43	-34	-22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-47	321	-25	-50	-26	-21	-35	-40	-32	-18
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	1.00	1.20	1.21	0.94	1.41	1.51	1.32	2.15	2.72
Price to Tangible Book Value (P/TBV)	0.00	1.09	1.31	1.32	1.03	1.53	1.65	1.39	2.27	2.86
Price to Revenue (P/Rev)	0.00	1.20	1.28	1.22	0.87	8.61	13.13	8.55	12.71	12.09
Price to Earnings (P/E)	0.00	3.98	3.29	2.94	1.96	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	25.11%	30.44%	33.98%	50.98%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	2.59	6.75	0.25	23.19	13.84	13.71	0.00	41.06
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.35	0.25	0.02	2.61	4.80	2.24	6.68	7.84
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.01	0.84	0.56	0.04	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.02	0.88	0.60	0.04	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.02	0.95	0.64	0.04	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.01	1.34	0.68	0.04	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-1.00	-0.87	-0.96	-0.92	-0.99	-0.91	-0.97	-0.97	-0.97
Leverage Ratio	0.00	1.40	1.27	1.34	1.31	1.28	1.27	1.31	1.32	1.30
Compound Leverage Factor	0.00	1.41	1.05	1.22	1.11	1.02	1.07	1.15	1.14	1.06
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	3.79	2.63	1.75	1.43	2.48	2.24	1.52	2.19	2.50
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	5.70	6.33	4.49	5.14	7.41	6.92	7.01	4.10	3.40
Quick Ratio	0.00	5.50	6.06	4.16	4.98	7.06	6.61	6.62	3.82	3.19
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	0.00	-79	-54	-57	-25	16	-24	17	-22
Operating Cash Flow to CapEx	-7,442.92%	94,068.97%	-21,552.07%	-797.88%	-4,587.85%	3,919.66%	-20,361.62%	-4,214.17%	-653.73%	-13,219.11%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.79	0.74	0.74	0.83	0.12	0.09	0.11	0.12	0.15
Accounts Receivable Turnover	0.00	16.83	6.67	9.17	6.86	2.88	1.03	1.55	1.37	2.03
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	17.37	18.97	20.01	22.08	3.41	2.38	3.07	3.17	4.07
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	21.69	54.75	39.80	53.20	126.95	353.92	235.46	266.94	180.08
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	21.69	54.75	39.80	53.20	126.95	353.92	235.46	266.94	180.08
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	-0.16	60	17	33	8.55	18	10	-7.89	15
Invested Capital Turnover	0.00	-2,546.19	14.80	53.96	27.75	18.13	1.30	4.68	4.90	6.60
Increase / (Decrease) in Invested Capital	0.00	0.00	60	17	33	8.71	-43	-6.37	-41	6.02
Enterprise Value (EV)	0.00	2.03	156	112	8.32	198	242	140	416	598
Market Capitalization	0.00	495	569	544	399	655	663	536	791	922
Book Value per Share	$0.00	$7.56	$7.39	$7.00	$6.26	$6.64	$6.21	$5.74	$5.17	$4.92
Tangible Book Value per Share	$0.00	$6.97	$6.81	$6.42	$5.70	$6.11	$5.68	$5.47	$4.90	$4.68
Total Capital	0.00	493	474	449	424	465	438	406	367	339
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-493	-413	-432	-391	-456	-420	-396	-375	-324
Capital Expenditures (CapEx)	0.98	0.35	0.39	0.80	0.93	0.36	0.19	0.59	0.90	0.31
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-43	18	-13	6.38	-17	-8.12	-1.36	-37	-14
Debt-free Net Working Capital (DFNWC)	0.00	449	359	327	302	357	337	329	260	212
Net Working Capital (NWC)	0.00	449	359	327	302	357	337	329	260	212
Net Nonoperating Expense (NNE)	13	-1.01	5.26	13	5.42	-1.91	5.19	7.67	5.91	7.95
Net Nonoperating Obligations (NNO)	0.00	-493	-413	-432	-391	-456	-420	-396	-375	-324
Total Depreciation and Amortization (D&A)	2.19	2.31	2.90	4.52	6.54	3.35	2.31	2.53	2.66	3.69
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-10.46%	4.09%	-2.97%	1.38%	-22.58%	-16.08%	-2.18%	-60.03%	-17.85%
Debt-free Net Working Capital to Revenue	0.00%	108.87%	80.48%	72.99%	65.38%	469.88%	667.66%	524.33%	417.79%	278.04%
Net Working Capital to Revenue	0.00%	108.87%	80.48%	72.99%	65.38%	469.88%	667.66%	524.33%	417.79%	278.04%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$4.78	($0.36)	($0.76)	($0.41)	($0.19)	($0.42)	($0.49)	($0.39)	($0.32)
Adjusted Weighted Average Basic Shares Outstanding	0.00	65.19M	66.74M	67.28M	70.58M	68.86M	76.21M	76.39M	76.13M	75.85M
Adjusted Diluted Earnings per Share	$0.00	$4.78	($0.37)	($0.76)	($0.41)	($0.18)	($0.42)	($0.49)	($0.39)	($0.32)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	65.25M	66.74M	67.28M	70.58M	68.86M	76.25M	76.40M	76.16M	75.88M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	64.04M	64.17M	67.83M	70.00M	70.57M	70.70M	71.05M	68.88M	69.58M
Normalized Net Operating Profit after Tax (NOPAT)	-35	308	-19	-38	-23	-16	-26	-30	-24	-16
Normalized NOPAT Margin	-1,339.82%	76.63%	-53.68%	-540.99%	-140.95%	-96.86%	-263.82%	-156.01%	-149.65%	-50.12%
Pre Tax Income Margin	-1,819.65%	79.61%	-64.54%	-706.91%	-167.07%	-113.46%	-314.84%	-195.49%	-185.15%	-57.33%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-24.49%

Frequently Asked Questions About Zymeworks' Financials

When does Zymeworks's financial year end?

According to the most recent income statement we have on file, Zymeworks' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Zymeworks' net income changed over the last 4 years?

Zymeworks' net income appears to be on a downward trend, with a most recent value of -$122.70 million in 2024, falling from -$180.55 million in 2020. The previous period was -$118.67 million in 2023.

What is Zymeworks's operating income?

Zymeworks's total operating income in 2024 was -$137.11 million, based on the following breakdown:

Total Gross Profit: $76.30 million
Total Operating Expenses: $213.41 million

How has Zymeworks revenue changed over the last 4 years?

Over the last 4 years, Zymeworks' total revenue changed from $38.95 million in 2020 to $76.30 million in 2024, a change of 95.9%.

How much debt does Zymeworks have?

Zymeworks' total liabilities were at $124.32 million at the end of 2024, a 7.1% increase from 2023, and a 11.2% decrease since 2021.

How much cash does Zymeworks have?

In the past 3 years, Zymeworks' cash and equivalents has ranged from $66.10 million in 2024 to $400.91 million in 2022, and is currently $66.10 million as of their latest financial filing in 2024.

How has Zymeworks' book value per share changed over the last 4 years?

Over the last 4 years, Zymeworks' book value per share changed from 0.00 in 2020 to 4.92 in 2024, a change of 491.8%.

Remove Ads

Related Companies

This page (NYSE:ZYME) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zymeworks (ZYME) Financials

Frequently Asked Questions About Zymeworks' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zymeworks (ZYME) Financials

Annual Income Statements for Zymeworks

Quarterly Income Statements for Zymeworks

Annual Cash Flow Statements for Zymeworks

Quarterly Cash Flow Statements for Zymeworks

Annual Balance Sheets for Zymeworks

Quarterly Balance Sheets for Zymeworks

Annual Metrics and Ratios for Zymeworks

Quarterly Metrics and Ratios for Zymeworks

Frequently Asked Questions About Zymeworks' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools